Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.58 |
| ▸ | CTSS | P25774 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | KLK1 | P06870 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.49 |
| ▸ | ECE1 | P42892 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5743448 | 0.88 | SYK (0.53) | CTSLCTSSATMCTSKKLK1 | |
| SCHEMBL5743450 | 0.88 | SYK (0.53) | CTSLCTSSATMCTSKKLK1 | |
| SCHEMBL5742255 | 0.84 | ATM (0.67) | CTSLCTSSATMKLK1 | |
| SCHEMBL17765000 | 0.84 | ATM (0.67) | CTSLCTSSATMKLK1 | |
| SCHEMBL5742261 | 0.84 | ATM (0.67) | CTSLCTSSATMKLK1 | |
| SCHEMBL265512 | 0.84 | CTSK (0.64) | CTSLCTSSCTSK | |
| SCHEMBL319160 | 0.84 | CTSK (0.64) | CTSLCTSSCTSK | |
| SCHEMBL2895983 | 0.84 | CTSK (0.64) | CTSLCTSSCTSK | |
| SCHEMBL8932367 | 0.83 | CTSL (0.62) | CTSLCTSSATMCTSKMME | |
| SCHEMBL19380440 | 0.81 | ATM (0.61) | CTSLCTSSATMKLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470678-B2 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2008-12-30 | — | — | US | disclosed |
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | ASTRAZENECA AB (SE) | 2005-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239766-A1 | Diphenylazetidinone derivatives for treating disorders of the lipid metabolism | CYP46A1, CYP27A1, CYP7A1 | CTSL 2060/4885CTSS 2276/4885ATM 4471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.